Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Other financing activities (2020 - 2025)

Pulmonx (LUNG) has disclosed Other financing activities for 4 consecutive years, with $23000.0 as the latest value for Q3 2025.

  • Quarterly Other financing activities changed N/A to $23000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $76000.0 through Sep 2025, up 43.4% year-over-year, with the annual reading at $53000.0 for FY2022, 29.27% up from the prior year.
  • Other financing activities for Q3 2025 was $23000.0 at Pulmonx, down from $53000.0 in the prior quarter.
  • The five-year high for Other financing activities was $100000.0 in Q1 2021, with the low at -$59000.0 in Q2 2021.
  • Average Other financing activities over 3 years is $29250.0, with a median of $38000.0 recorded in 2022.
  • Peak annual rise in Other financing activities hit 75.0% in 2021, while the deepest fall reached 102.5% in 2021.
  • Over 3 years, Other financing activities stood at -$59000.0 in 2021, then soared by 189.83% to $53000.0 in 2022, then plummeted by 56.6% to $23000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $23000.0, $53000.0, and -$59000.0 for Q3 2025, Q4 2022, and Q2 2021 respectively.